Bone marrow biopsy (BM) morphology in patients with chronic myeloid leukemia (CML) treated with STI571

被引：0
|
作者：
Chiu, A
Silver, R
Rosamillia, M
Chadburn, A
机构：
[1] Cornell Univ, Weill Med Coll, New York, NY USA
[2] Novartis Pharmaceut AG, Basel, Switzerland
来源：
MODERN PATHOLOGY | 2001年 / 14卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
934
引用
收藏
页码：159A / 159A
页数：1
相关论文
共 50 条
  • [31] Glivec (STI571) in the treatment of patients with chronic myeloid leukemia (CML) relapsing in accelerated or blastic phase after allogenic stem cell transplantation.
    Wassmann, B
    Pfeifer, H
    Scheuring, U
    Brueck, P
    Binckebank, A
    Atta, J
    Martin, H
    Gschaidmeier, H
    Thiede, C
    Bornhauser, M
    Hoelzer, D
    Ottmann, OG
    BLOOD, 2001, 98 (11) : 140A - 140A
  • [32] Treatment of accelerated phase of Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML AP) with imatinib mesylate (STI571).
    Kantarjian, HM
    O'Brien, S
    Cortes, J
    Faderl, S
    Giles, F
    Thomas, D
    Garcia-Manero, G
    Albitar, M
    Rios, MB
    Shan, J
    Issa, JP
    Resta, D
    Capdeville, R
    Keating, MJ
    Freireich, EJ
    Talpaz, M
    BLOOD, 2001, 98 (11) : 141A - 141A
  • [33] Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis
    Beham-Schmid, C
    Apfelbeck, U
    Sill, H
    Tsybrovsky, O
    Höfler, G
    Haas, OA
    Linkesch, W
    BLOOD, 2002, 99 (01) : 381 - 383
  • [34] The Effects of Genistein and STI571 (Imatinib) on Signal Protein Levels Affecting Chronic Myeloid Leukemia
    Armutcuoglu, Nur Erden
    Kasap, Yesim Korkmaz
    Yurtcu, Erkan
    GAZI MEDICAL JOURNAL, 2018, 29 (03): : 187 - 190
  • [35] Restoration of sensitivity to STI571 in ST1571-resistant chronic myeloid leukemia cells
    Tipping, AJ
    Mahon, FX
    Lagarde, V
    Goldman, JM
    Melo, JV
    BLOOD, 2001, 98 (13) : 3864 - 3867
  • [36] Morphologic findings in peripheral blood and bone marrow of STI571-treated chronic myelogenous leukemia patients.
    Launder, TM
    Druker, BJ
    Mauro, MJ
    O'Dwyer, ME
    Resta, D
    Braziel, RM
    BLOOD, 2000, 96 (11) : 735A - 735A
  • [37] The effect of Gleevec (STI571;imatinib mesylate) in patients with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) with secondary chromosomal aberrations.
    Mohamed, AN
    Pemberton, P
    Zonder, JA
    Homisha, S
    Ford, J
    Schiffer, CA
    BLOOD, 2001, 98 (11) : 560A - 560A
  • [38] Pharmacogenetic analysis of cytogenetic response in chronic myelogenous leukemia patients treated with imatinib (Glivec®/Gleevec™, STI571).
    Malinowski, RH
    Dressman, M
    McLean, LA
    Gathmann, I
    Capdeville, R
    BLOOD, 2002, 100 (11) : 547A - 547A
  • [39] Marrow morphology of chronic myelogenous leukemia in patients treated with imatinib mesylate (Gleevac, Sti-571): Correlation with cytogenetic response
    Racke, F
    Allan, RW
    Miller, C
    Weir, EG
    LABORATORY INVESTIGATION, 2005, 85 : 248A - 248A
  • [40] Lack of cytogenetic response is an adverse prognostic factor for relapse of chronic phase CML patients treated with imatinib mesylate (STI571).
    O'Dwyer, M
    Mauro, MJ
    Blasdel, C
    Farnsworth, M
    Kurilik, G
    Fong, D
    Hsieh, YC
    Mori, M
    Capdeville, R
    Druker, BJ
    BLOOD, 2001, 98 (11) : 137A - 138A
12345